DR info

臨床試験数 : 52 / 薬物数 : 68 - (DrugBank : 27) / 標的遺伝子数 : 18 - 標的パスウェイ数 : 111

薬物ごとの開発者（Primary Sponsor）、臨床試験情報（抜粋）です。

Anti-BAFFR antibody
   Novartis Pharma AG
      2018   Phase 2;Phase 3   EUCTR2017-001555-32-NL   Belgium;Canada;Czech Republic;Denmark;Germany;Japan;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2018   Phase 2;Phase 3   EUCTR2017-001555-32-GB   Argentina;Belgium;Canada;Czech Republic;Denmark;Germany;Japan;Netherlands;Singapore;Spain;Sweden;Switzerland;United Kingdom;United States;
      2018   Phase 2;Phase 3   EUCTR2017-001555-32-DK   Belgium;Canada;Czech Republic;Denmark;Germany;Japan;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2018   Phase 2;Phase 3   EUCTR2017-001555-32-DE   Argentina;Belgium;Canada;Czech Republic;Czechia;Denmark;Germany;Japan;Netherlands;Singapore;Spain;Sweden;Switzerland;United Kingdom;United States;
      2018   Phase 2;Phase 3   EUCTR2017-001555-32-BE   Argentina;Belgium;Canada;Czech Republic;Czechia;Denmark;Germany;Japan;Netherlands;Singapore;Spain;Sweden;Switzerland;United Kingdom;United States;
      2017   Phase 2;Phase 3   EUCTR2017-001555-32-SE   Belgium;Canada;Czech Republic;Denmark;Germany;Japan;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
Anti-BAFFr antibody
   Novartis Farmacéutica S.A
      2017   Phase 2;Phase 3   EUCTR2017-001555-32-ES   Belgium;Canada;Czech Republic;Denmark;Germany;Japan;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
Azathioprine
   Radboud University
      2017   Phase 4   NCT02900443   Netherlands;
   University of Sao Paulo General Hospital
      2003   Phase 4   NCT02463331   -
   Veloxis Pharmaceuticals
      2007   Phase 2   NCT00608894   Canada;United States;
Budesonid
   Umeå University Hospital
      2020   Phase 4   EUCTR2018-003381-14-SE   Sweden;
Budesonide
   Dr. Falk Pharma GmbH
      2001   Phase 2/Phase 3   NCT00838214   Germany;
   Mayo Clinic
      2007   -   NCT00587119   United States;
Calcium
   Juntendo University School of Medicine
      2014   -   JPRN-UMIN000013659   Japan;
Cannabidiol
   Stero Biotechs Ltd.
      2019   Phase 2   NCT04129489   Israel;
Chloroquine diphosphate
   University of Sao Paulo General Hospital
      2003   Phase 4   NCT02463331   -
      2002   Phase 4   NCT01980745   Brazil;
Collection of samples
   Institut National de la Santé Et de la Recherche Médicale, France
      2021   -   NCT04902807   -
Cyclosporin A
   West China Hospital
      2021   Phase 4   NCT04376528   China;
Cyclosporine-A
   Tehran University of Medical Sciences
      2005   Phase 3   NCT01170351   Iran, Islamic Republic of;
Denosumab
   Juntendo University School of Medicine
      2014   -   JPRN-UMIN000013659   Japan;
Erythropoietin
   Northwestern University
      2019   Early Phase 1   NCT03842254   United States;
Gold
   The Sixth People's Hospital Affiliated To Shanghai Jiaotong University
      2020   -   ChiCTR2000031051   China;
High protein high fiber diet
   Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
      2012   -   NCT01655121   Mexico;
Ianalumab
   Novartis Pharma AG
      2018   Phase 2;Phase 3   EUCTR2017-001555-32-NL   Belgium;Canada;Czech Republic;Denmark;Germany;Japan;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2018   Phase 2;Phase 3   EUCTR2017-001555-32-GB   Argentina;Belgium;Canada;Czech Republic;Denmark;Germany;Japan;Netherlands;Singapore;Spain;Sweden;Switzerland;United Kingdom;United States;
      2018   Phase 2;Phase 3   EUCTR2017-001555-32-DK   Belgium;Canada;Czech Republic;Denmark;Germany;Japan;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2018   Phase 2;Phase 3   EUCTR2017-001555-32-DE   Argentina;Belgium;Canada;Czech Republic;Czechia;Denmark;Germany;Japan;Netherlands;Singapore;Spain;Sweden;Switzerland;United Kingdom;United States;
      2018   Phase 2;Phase 3   EUCTR2017-001555-32-BE   Argentina;Belgium;Canada;Czech Republic;Czechia;Denmark;Germany;Japan;Netherlands;Singapore;Spain;Sweden;Switzerland;United Kingdom;United States;
      2017   Phase 2;Phase 3   EUCTR2017-001555-32-SE   Belgium;Canada;Czech Republic;Denmark;Germany;Japan;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      -   Phase 2;Phase 3   EUCTR2017-001555-32-CZ   Argentina;Belgium;Canada;Czech Republic;Czechia;Denmark;Germany;Japan;Netherlands;Singapore;Spain;Sweden;Switzerland;United Kingdom;United States;
IgG IL2/RO7049665
   F. HOFFMANN - LA ROCHE LTD.
      2021   Phase 2   EUCTR2020-003990-23-IT   Australia;Canada;Germany;Italy;Korea, Democratic People's Republic of;Korea, Republic of;Netherlands;New Zealand;Portugal;United Kingdom;
   F. Hoffmann-La Roche Ltd
      2021   Phase 2   EUCTR2020-003990-23-PT   Australia;Canada;Germany;Italy;Korea, Republic of;Netherlands;New Zealand;Portugal;United Kingdom;
      2021   Phase 2   EUCTR2020-003990-23-NL   Australia;Canada;Germany;Italy;Korea, Republic of;Netherlands;New Zealand;Portugal;United Kingdom;
      2021   Phase 2   EUCTR2020-003990-23-DE   Australia;Canada;Germany;Italy;Korea, Republic of;Netherlands;New Zealand;Portugal;United Kingdom;
Inflectra (Infliximab)
   University Medical Centre Hamburg-Eppendorf
      2018   Phase 2   EUCTR2017-003311-19-DE   Germany;
JKB-122
   TaiwanJ Pharmaceuticals Co., Ltd
      2020   Phase 2   NCT04371718   -
      2016   Phase 2   NCT02556372   United States;
JKB-122 in capsule or tablet form
   TaiwanJ Pharmaceuticals Co., Ltd
      2020   Phase 1   NCT04313205   -
LCP-Tacro (tacrolimus)
   Veloxis Pharmaceuticals
      2007   Phase 2   NCT00608894   Canada;United States;
Methylprednisolone and Mycophenolate mofetil
   Xiaoli Fan
      2021   Phase 4   NCT04933292   China;
Methylprednisolone and azathioprine
   Xiaoli Fan
      2021   Phase 4   NCT04933292   China;
Metronidazole
   Cliniques universitaires Saint-Luc- Université Catholique de Louvain
      2016   -   NCT03069976   Belgium;
Minodronic acid
   Juntendo University School of Medicine
      2014   -   JPRN-UMIN000013659   Japan;
Mycophenolate mofeti
   Leiden university medical centre
      2018   Phase 4   EUCTR2016-001038-91-BE   Belgium;Netherlands;
      2016   Phase 4   EUCTR2016-001038-91-NL   Netherlands;
Mycophenolate mofetil
   Radboud University
      2017   Phase 4   NCT02900443   Netherlands;
Orbcel-C
   University of Birmingham
      2018   Phase 1/Phase 2   NCT02997878   United Kingdom;
Orencia® (Abatacept)
   Stuart Knechtle, M.D.
      2020   Phase 1   NCT04203875   United States;
PREDNISOLONE SODIUM SUCCINATE
   Leiden university medical centre
      2018   Phase 4   EUCTR2016-001038-91-BE   Belgium;Netherlands;
      2016   Phase 4   EUCTR2016-001038-91-NL   Netherlands;
Prednisolon
   Umeå University Hospital
      2020   Phase 4   EUCTR2018-003381-14-SE   Sweden;
Prednisone
   Dr. Falk Pharma GmbH
      2001   Phase 2/Phase 3   NCT00838214   Germany;
   University of Sao Paulo General Hospital
      2003   Phase 4   NCT02463331   -
RO7049665
   Hoffmann-La Roche
      2021   Phase 2   NCT04790916   Australia;Canada;Germany;Italy;Korea, Republic of;Netherlands;Portugal;United Kingdom;
RO7049665/IgG-IL2/ IgG-IL2ND2
   F. HOFFMANN - LA ROCHE LTD.
      2021   Phase 2   EUCTR2020-003990-23-IT   Australia;Canada;Germany;Italy;Korea, Democratic People's Republic of;Korea, Republic of;Netherlands;New Zealand;Portugal;United Kingdom;
   F. Hoffmann-La Roche Ltd
      2021   Phase 2   EUCTR2020-003990-23-PT   Australia;Canada;Germany;Italy;Korea, Republic of;Netherlands;New Zealand;Portugal;United Kingdom;
      2021   Phase 2   EUCTR2020-003990-23-NL   Australia;Canada;Germany;Italy;Korea, Republic of;Netherlands;New Zealand;Portugal;United Kingdom;
      2021   Phase 2   EUCTR2020-003990-23-DE   Australia;Canada;Germany;Italy;Korea, Republic of;Netherlands;New Zealand;Portugal;United Kingdom;
Raptiva 100 mg/ml powder and solvent for solution for injection
   Merck Serono International S.A.
      2009   -   EUCTR2007-001377-28-PT   Austria;France;Germany;Netherlands;Portugal;
      2008   -   EUCTR2007-001377-28-NL   Austria;France;Germany;Netherlands;Portugal;
      2008   -   EUCTR2007-001377-28-FR   Austria;France;Germany;Netherlands;Portugal;
      2008   -   EUCTR2007-001377-28-DE   Austria;France;Germany;Netherlands;Portugal;
      2008   -   EUCTR2007-001377-28-AT   Austria;France;Germany;Netherlands;Portugal;
Regulatory T cells
   Nanjing Medical University
      2016   Phase 1/Phase 2   NCT02704338   -
Risedronic acid
   Juntendo University School of Medicine
      2014   -   JPRN-UMIN000013659   Japan;
SPIF
   Christopher O'Brien, MD
      2014   Phase 1   NCT02239562   United States;
Synthetic PreImplantation Factor
   Christopher O'Brien, MD
      2019   Phase 2   NCT03593460   -
Tacrolimus
   Hiroshima University Hospital
      2019   -   JPRN-UMIN000030743   Japan;
Treatment with azathioprin
   Rigshospitalet, Denmark
      2005   Phase 4   NCT00687180   Denmark;
Treatment with mycophenolat mofetil
   Rigshospitalet, Denmark
      2005   Phase 4   NCT00687180   Denmark;
Ursodeoxycholic acid combination of immunosuppressive agents
   Xiaoli Fan
      2016   -   NCT02936596   China;
VAY736
   Novartis Farmacéutica S.A
      2017   Phase 2;Phase 3   EUCTR2017-001555-32-ES   Belgium;Canada;Czech Republic;Denmark;Germany;Japan;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
   Novartis Pharma AG
      2018   Phase 2;Phase 3   EUCTR2017-001555-32-NL   Belgium;Canada;Czech Republic;Denmark;Germany;Japan;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2018   Phase 2;Phase 3   EUCTR2017-001555-32-GB   Argentina;Belgium;Canada;Czech Republic;Denmark;Germany;Japan;Netherlands;Singapore;Spain;Sweden;Switzerland;United Kingdom;United States;
      2018   Phase 2;Phase 3   EUCTR2017-001555-32-DK   Belgium;Canada;Czech Republic;Denmark;Germany;Japan;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2018   Phase 2;Phase 3   EUCTR2017-001555-32-DE   Argentina;Belgium;Canada;Czech Republic;Czechia;Denmark;Germany;Japan;Netherlands;Singapore;Spain;Sweden;Switzerland;United Kingdom;United States;
      2018   Phase 2;Phase 3   EUCTR2017-001555-32-BE   Argentina;Belgium;Canada;Czech Republic;Czechia;Denmark;Germany;Japan;Netherlands;Singapore;Spain;Sweden;Switzerland;United Kingdom;United States;
      2017   Phase 2;Phase 3   EUCTR2017-001555-32-SE   Belgium;Canada;Czech Republic;Denmark;Germany;Japan;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      -   Phase 2;Phase 3   EUCTR2017-001555-32-CZ   Argentina;Belgium;Canada;Czech Republic;Czechia;Denmark;Germany;Japan;Netherlands;Singapore;Spain;Sweden;Switzerland;United Kingdom;United States;
   Novartis Pharmaceuticals
      2018   Phase 2/Phase 3   NCT03217422   Argentina;Belgium;Canada;Czechia;Denmark;Germany;Japan;Netherlands;Singapore;Spain;Sweden;Switzerland;United Kingdom;United States;
Various
   Umeå University Hospital
      2020   Phase 4   EUCTR2018-003381-14-SE   Sweden;
Vitamin D
   Juntendo University School of Medicine
      2014   -   JPRN-UMIN000013659   Japan;
Zoledronic acid
   Hyogo college of medicine
      2018   -   JPRN-UMIN000031353   Japan;